Medical devices are prosperous, and the company expects net profit to increase by more than 30,000% in the first three quarters of this year

Up to now, more than 50 pharmaceutical companies have disclosed performance forecasts, and a total of 90% of companies have good
results.
Among the enterprises with growth in performance, a number of medical equipment companies have performed well, among which Jiuan Medical expects its net profit to increase by more than 30,000%
in the first three quarters.
On the evening of October 14, Jiuan Medical disclosed its performance forecast for the first three quarters, expecting the net profit attributable to shareholders of listed companies in the first three quarters to be 16 billion yuan to 16.
3 billion yuan, a year-on-year increase of 31818.
29% to 32416.
76%; In the third quarter alone, the company's net profit attributable to shareholders of listed companies was 756 million yuan to 1.
056 billion yuan, turning losses into profits
year-on-year.
For the reasons for the surge in performance, the company said that during the reporting period, affected by the epidemic, the company's iHealth kit products in the United States market demand was strong, the company actively took various measures to achieve effective operation of production and supply chain, continued to do a good job in order fulfillment and market development, ensured the timely delivery of customer orders, and the company's performance increased
significantly compared with the same period last year 。 Some analysts believe that the emergence of the epidemic has catalyzed the rapid growth of the medical device industry, especially in the case of the reduction of overseas independent production, domestic cost-effective medical devices have ushered in the opportunity to seize the overseas market, so that the market share of domestic enterprises overseas continues to grow
.
In addition to Jiuan Medical, BGI Intelligent Manufacturing and CapBiologics also have outstanding performance, and both expect the company's net profit to double
in the first three quarters.
Among them, Mindray's performance in the first three quarters of this year has exceeded the net profit of last year, and is expected to reach 8.
088 billion yuan
.
As for the growth of performance, Mindray said that it benefited from the vigorous development of new domestic medical infrastructure and the continuous recovery of global routine business, while the company continued to strengthen internal management and continuously improve operating efficiency, achieving stable and healthy growth in
the company's operating income and net profit.
From the perspective of the main business of these performance forecasting companies, although they belong to different segments, the performance growth reflects the relative prosperity of the industry and the company's strong competitiveness
.
Looking ahead, many institutions believe that under the general trend of new medical infrastructure, in the long run, medicine may become an important part of "new infrastructure", and the medical device industry is expected to usher in a larger demand release
.
Favorable policies support the innovation and development of
the medical device industry.
Recently, the Health Commission issued a notice that it intends to use financial subsidized loans to modernize and transform medical equipment, and intends to issue supporting policies in the near future to further clarify the policy
of using financial subsidized loans to modernize and transform medical equipment in hospitals.
In principle, the relevant financial subsidized interest loans are fully liberalized to all public and non-public medical institutions, and the loan amount of each hospital is not less than 20 million
.
The direction of loan use also includes the purchase
of various medical equipment such as diagnosis and treatment, clinical laboratory, critical care, rehabilitation, scientific research and transformation.
This new policy is considered by the industry to be the imminent
release of hundreds of billions of medical device market demand.
Kaiyuan Securities said that in 2022, indicators such as domestic public medical budget, public hospital budget revenue, number of domestic medical and health projects and total investment will increase significantly, and new medical infrastructure investment is expected to maintain a high level
for a long time.
The central government's subsidized interest loan once again reflects the country's emphasis on new medical infrastructure, and the investment in new medical infrastructure is expected to maintain a high level throughout the 14th Five-Year Plan period, and the high prosperity of the industry is expected to continue
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.